Managing pleural malignancy
Pleural malignancy is a growing problem, with malignant pleural effusions (MPEs) affecting 70 per 100,000 people every year. Around 15% of all cancer patients are diagnosed with pleural malignancy during their cancer journey, and they are treated by general and respiratory physicians alike. MPEs usu...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Lynch, Geraldine A. [verfasserIn] Bibby, Anna [verfasserIn] Maskell, Nick A. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2023 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Medicine - [Oxford] : Elsevier, 2002, 51, Seite 880-887 |
|---|---|
| Übergeordnetes Werk: |
volume:51 ; pages:880-887 |
| DOI / URN: |
10.1016/j.mpmed.2023.09.008 |
|---|
| Katalog-ID: |
ELV065638786 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV065638786 | ||
| 003 | DE-627 | ||
| 005 | 20231118093014.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231118s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mpmed.2023.09.008 |2 doi | |
| 035 | |a (DE-627)ELV065638786 | ||
| 035 | |a (ELSEVIER)S1357-3039(23)00229-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Lynch, Geraldine A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Managing pleural malignancy |
| 264 | 1 | |c 2023 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Pleural malignancy is a growing problem, with malignant pleural effusions (MPEs) affecting 70 per 100,000 people every year. Around 15% of all cancer patients are diagnosed with pleural malignancy during their cancer journey, and they are treated by general and respiratory physicians alike. MPEs usually indicate advanced or aggressive disease, with median survival typically 6–12 months. Symptoms can be debilitating, so effusion management and symptom control form key aspects of care. Management options for MPE have grown in recent years, and important differences in the benefits and disadvantages of the various methods mean that patient choice is paramount. This review covers the investigation, diagnosis and management of individuals with suspected MPE. It details the strategies available for definitive MPE management, explores which approaches to consider in different situations, and describes how to manage potential complications. | ||
| 650 | 4 | |a Indwelling pleural catheter | |
| 650 | 4 | |a malignant pleural effusion | |
| 650 | 4 | |a pleural biopsy | |
| 650 | 4 | |a pleurodesis | |
| 700 | 1 | |a Bibby, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Maskell, Nick A. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicine |d [Oxford] : Elsevier, 2002 |g 51, Seite 880-887 |w (DE-627)362773971 |w (DE-600)2100582-5 |w (DE-576)271585617 |x 1878-9390 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g pages:880-887 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_4251 | ||
| 936 | b | k | |a 44.00 |j Medizin: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 51 |h 880-887 | ||
| author_variant |
g a l ga gal a b ab n a m na nam |
|---|---|
| matchkey_str |
article:18789390:2023----::aaigluaml |
| hierarchy_sort_str |
2023 |
| bklnumber |
44.00 |
| publishDate |
2023 |
| allfields |
10.1016/j.mpmed.2023.09.008 doi (DE-627)ELV065638786 (ELSEVIER)S1357-3039(23)00229-3 DE-627 ger DE-627 rda eng 610 VZ 44.00 bkl Lynch, Geraldine A. verfasserin aut Managing pleural malignancy 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Pleural malignancy is a growing problem, with malignant pleural effusions (MPEs) affecting 70 per 100,000 people every year. Around 15% of all cancer patients are diagnosed with pleural malignancy during their cancer journey, and they are treated by general and respiratory physicians alike. MPEs usually indicate advanced or aggressive disease, with median survival typically 6–12 months. Symptoms can be debilitating, so effusion management and symptom control form key aspects of care. Management options for MPE have grown in recent years, and important differences in the benefits and disadvantages of the various methods mean that patient choice is paramount. This review covers the investigation, diagnosis and management of individuals with suspected MPE. It details the strategies available for definitive MPE management, explores which approaches to consider in different situations, and describes how to manage potential complications. Indwelling pleural catheter malignant pleural effusion pleural biopsy pleurodesis Bibby, Anna verfasserin aut Maskell, Nick A. verfasserin aut Enthalten in Medicine [Oxford] : Elsevier, 2002 51, Seite 880-887 (DE-627)362773971 (DE-600)2100582-5 (DE-576)271585617 1878-9390 nnns volume:51 pages:880-887 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_31 GBV_ILN_2004 GBV_ILN_2111 GBV_ILN_2336 GBV_ILN_4251 44.00 Medizin: Allgemeines VZ AR 51 880-887 |
| spelling |
10.1016/j.mpmed.2023.09.008 doi (DE-627)ELV065638786 (ELSEVIER)S1357-3039(23)00229-3 DE-627 ger DE-627 rda eng 610 VZ 44.00 bkl Lynch, Geraldine A. verfasserin aut Managing pleural malignancy 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Pleural malignancy is a growing problem, with malignant pleural effusions (MPEs) affecting 70 per 100,000 people every year. Around 15% of all cancer patients are diagnosed with pleural malignancy during their cancer journey, and they are treated by general and respiratory physicians alike. MPEs usually indicate advanced or aggressive disease, with median survival typically 6–12 months. Symptoms can be debilitating, so effusion management and symptom control form key aspects of care. Management options for MPE have grown in recent years, and important differences in the benefits and disadvantages of the various methods mean that patient choice is paramount. This review covers the investigation, diagnosis and management of individuals with suspected MPE. It details the strategies available for definitive MPE management, explores which approaches to consider in different situations, and describes how to manage potential complications. Indwelling pleural catheter malignant pleural effusion pleural biopsy pleurodesis Bibby, Anna verfasserin aut Maskell, Nick A. verfasserin aut Enthalten in Medicine [Oxford] : Elsevier, 2002 51, Seite 880-887 (DE-627)362773971 (DE-600)2100582-5 (DE-576)271585617 1878-9390 nnns volume:51 pages:880-887 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_31 GBV_ILN_2004 GBV_ILN_2111 GBV_ILN_2336 GBV_ILN_4251 44.00 Medizin: Allgemeines VZ AR 51 880-887 |
| allfields_unstemmed |
10.1016/j.mpmed.2023.09.008 doi (DE-627)ELV065638786 (ELSEVIER)S1357-3039(23)00229-3 DE-627 ger DE-627 rda eng 610 VZ 44.00 bkl Lynch, Geraldine A. verfasserin aut Managing pleural malignancy 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Pleural malignancy is a growing problem, with malignant pleural effusions (MPEs) affecting 70 per 100,000 people every year. Around 15% of all cancer patients are diagnosed with pleural malignancy during their cancer journey, and they are treated by general and respiratory physicians alike. MPEs usually indicate advanced or aggressive disease, with median survival typically 6–12 months. Symptoms can be debilitating, so effusion management and symptom control form key aspects of care. Management options for MPE have grown in recent years, and important differences in the benefits and disadvantages of the various methods mean that patient choice is paramount. This review covers the investigation, diagnosis and management of individuals with suspected MPE. It details the strategies available for definitive MPE management, explores which approaches to consider in different situations, and describes how to manage potential complications. Indwelling pleural catheter malignant pleural effusion pleural biopsy pleurodesis Bibby, Anna verfasserin aut Maskell, Nick A. verfasserin aut Enthalten in Medicine [Oxford] : Elsevier, 2002 51, Seite 880-887 (DE-627)362773971 (DE-600)2100582-5 (DE-576)271585617 1878-9390 nnns volume:51 pages:880-887 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_31 GBV_ILN_2004 GBV_ILN_2111 GBV_ILN_2336 GBV_ILN_4251 44.00 Medizin: Allgemeines VZ AR 51 880-887 |
| allfieldsGer |
10.1016/j.mpmed.2023.09.008 doi (DE-627)ELV065638786 (ELSEVIER)S1357-3039(23)00229-3 DE-627 ger DE-627 rda eng 610 VZ 44.00 bkl Lynch, Geraldine A. verfasserin aut Managing pleural malignancy 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Pleural malignancy is a growing problem, with malignant pleural effusions (MPEs) affecting 70 per 100,000 people every year. Around 15% of all cancer patients are diagnosed with pleural malignancy during their cancer journey, and they are treated by general and respiratory physicians alike. MPEs usually indicate advanced or aggressive disease, with median survival typically 6–12 months. Symptoms can be debilitating, so effusion management and symptom control form key aspects of care. Management options for MPE have grown in recent years, and important differences in the benefits and disadvantages of the various methods mean that patient choice is paramount. This review covers the investigation, diagnosis and management of individuals with suspected MPE. It details the strategies available for definitive MPE management, explores which approaches to consider in different situations, and describes how to manage potential complications. Indwelling pleural catheter malignant pleural effusion pleural biopsy pleurodesis Bibby, Anna verfasserin aut Maskell, Nick A. verfasserin aut Enthalten in Medicine [Oxford] : Elsevier, 2002 51, Seite 880-887 (DE-627)362773971 (DE-600)2100582-5 (DE-576)271585617 1878-9390 nnns volume:51 pages:880-887 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_31 GBV_ILN_2004 GBV_ILN_2111 GBV_ILN_2336 GBV_ILN_4251 44.00 Medizin: Allgemeines VZ AR 51 880-887 |
| allfieldsSound |
10.1016/j.mpmed.2023.09.008 doi (DE-627)ELV065638786 (ELSEVIER)S1357-3039(23)00229-3 DE-627 ger DE-627 rda eng 610 VZ 44.00 bkl Lynch, Geraldine A. verfasserin aut Managing pleural malignancy 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Pleural malignancy is a growing problem, with malignant pleural effusions (MPEs) affecting 70 per 100,000 people every year. Around 15% of all cancer patients are diagnosed with pleural malignancy during their cancer journey, and they are treated by general and respiratory physicians alike. MPEs usually indicate advanced or aggressive disease, with median survival typically 6–12 months. Symptoms can be debilitating, so effusion management and symptom control form key aspects of care. Management options for MPE have grown in recent years, and important differences in the benefits and disadvantages of the various methods mean that patient choice is paramount. This review covers the investigation, diagnosis and management of individuals with suspected MPE. It details the strategies available for definitive MPE management, explores which approaches to consider in different situations, and describes how to manage potential complications. Indwelling pleural catheter malignant pleural effusion pleural biopsy pleurodesis Bibby, Anna verfasserin aut Maskell, Nick A. verfasserin aut Enthalten in Medicine [Oxford] : Elsevier, 2002 51, Seite 880-887 (DE-627)362773971 (DE-600)2100582-5 (DE-576)271585617 1878-9390 nnns volume:51 pages:880-887 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_31 GBV_ILN_2004 GBV_ILN_2111 GBV_ILN_2336 GBV_ILN_4251 44.00 Medizin: Allgemeines VZ AR 51 880-887 |
| language |
English |
| source |
Enthalten in Medicine 51, Seite 880-887 volume:51 pages:880-887 |
| sourceStr |
Enthalten in Medicine 51, Seite 880-887 volume:51 pages:880-887 |
| format_phy_str_mv |
Article |
| bklname |
Medizin: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Indwelling pleural catheter malignant pleural effusion pleural biopsy pleurodesis |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Medicine |
| authorswithroles_txt_mv |
Lynch, Geraldine A. @@aut@@ Bibby, Anna @@aut@@ Maskell, Nick A. @@aut@@ |
| publishDateDaySort_date |
2023-01-01T00:00:00Z |
| hierarchy_top_id |
362773971 |
| dewey-sort |
3610 |
| id |
ELV065638786 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">ELV065638786</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20231118093014.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">231118s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.mpmed.2023.09.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV065638786</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1357-3039(23)00229-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lynch, Geraldine A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Managing pleural malignancy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pleural malignancy is a growing problem, with malignant pleural effusions (MPEs) affecting 70 per 100,000 people every year. Around 15% of all cancer patients are diagnosed with pleural malignancy during their cancer journey, and they are treated by general and respiratory physicians alike. MPEs usually indicate advanced or aggressive disease, with median survival typically 6–12 months. Symptoms can be debilitating, so effusion management and symptom control form key aspects of care. Management options for MPE have grown in recent years, and important differences in the benefits and disadvantages of the various methods mean that patient choice is paramount. This review covers the investigation, diagnosis and management of individuals with suspected MPE. It details the strategies available for definitive MPE management, explores which approaches to consider in different situations, and describes how to manage potential complications.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Indwelling pleural catheter</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">malignant pleural effusion</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pleural biopsy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pleurodesis</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bibby, Anna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maskell, Nick A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Medicine</subfield><subfield code="d">[Oxford] : Elsevier, 2002</subfield><subfield code="g">51, Seite 880-887</subfield><subfield code="w">(DE-627)362773971</subfield><subfield code="w">(DE-600)2100582-5</subfield><subfield code="w">(DE-576)271585617</subfield><subfield code="x">1878-9390</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:51</subfield><subfield code="g">pages:880-887</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="j">Medizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">51</subfield><subfield code="h">880-887</subfield></datafield></record></collection>
|
| author |
Lynch, Geraldine A. |
| spellingShingle |
Lynch, Geraldine A. ddc 610 bkl 44.00 misc Indwelling pleural catheter misc malignant pleural effusion misc pleural biopsy misc pleurodesis Managing pleural malignancy |
| authorStr |
Lynch, Geraldine A. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)362773971 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1878-9390 |
| topic_title |
610 VZ 44.00 bkl Managing pleural malignancy Indwelling pleural catheter malignant pleural effusion pleural biopsy pleurodesis |
| topic |
ddc 610 bkl 44.00 misc Indwelling pleural catheter misc malignant pleural effusion misc pleural biopsy misc pleurodesis |
| topic_unstemmed |
ddc 610 bkl 44.00 misc Indwelling pleural catheter misc malignant pleural effusion misc pleural biopsy misc pleurodesis |
| topic_browse |
ddc 610 bkl 44.00 misc Indwelling pleural catheter misc malignant pleural effusion misc pleural biopsy misc pleurodesis |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Medicine |
| hierarchy_parent_id |
362773971 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Medicine |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)362773971 (DE-600)2100582-5 (DE-576)271585617 |
| title |
Managing pleural malignancy |
| ctrlnum |
(DE-627)ELV065638786 (ELSEVIER)S1357-3039(23)00229-3 |
| title_full |
Managing pleural malignancy |
| author_sort |
Lynch, Geraldine A. |
| journal |
Medicine |
| journalStr |
Medicine |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
zzz |
| container_start_page |
880 |
| author_browse |
Lynch, Geraldine A. Bibby, Anna Maskell, Nick A. |
| container_volume |
51 |
| class |
610 VZ 44.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Lynch, Geraldine A. |
| doi_str_mv |
10.1016/j.mpmed.2023.09.008 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
managing pleural malignancy |
| title_auth |
Managing pleural malignancy |
| abstract |
Pleural malignancy is a growing problem, with malignant pleural effusions (MPEs) affecting 70 per 100,000 people every year. Around 15% of all cancer patients are diagnosed with pleural malignancy during their cancer journey, and they are treated by general and respiratory physicians alike. MPEs usually indicate advanced or aggressive disease, with median survival typically 6–12 months. Symptoms can be debilitating, so effusion management and symptom control form key aspects of care. Management options for MPE have grown in recent years, and important differences in the benefits and disadvantages of the various methods mean that patient choice is paramount. This review covers the investigation, diagnosis and management of individuals with suspected MPE. It details the strategies available for definitive MPE management, explores which approaches to consider in different situations, and describes how to manage potential complications. |
| abstractGer |
Pleural malignancy is a growing problem, with malignant pleural effusions (MPEs) affecting 70 per 100,000 people every year. Around 15% of all cancer patients are diagnosed with pleural malignancy during their cancer journey, and they are treated by general and respiratory physicians alike. MPEs usually indicate advanced or aggressive disease, with median survival typically 6–12 months. Symptoms can be debilitating, so effusion management and symptom control form key aspects of care. Management options for MPE have grown in recent years, and important differences in the benefits and disadvantages of the various methods mean that patient choice is paramount. This review covers the investigation, diagnosis and management of individuals with suspected MPE. It details the strategies available for definitive MPE management, explores which approaches to consider in different situations, and describes how to manage potential complications. |
| abstract_unstemmed |
Pleural malignancy is a growing problem, with malignant pleural effusions (MPEs) affecting 70 per 100,000 people every year. Around 15% of all cancer patients are diagnosed with pleural malignancy during their cancer journey, and they are treated by general and respiratory physicians alike. MPEs usually indicate advanced or aggressive disease, with median survival typically 6–12 months. Symptoms can be debilitating, so effusion management and symptom control form key aspects of care. Management options for MPE have grown in recent years, and important differences in the benefits and disadvantages of the various methods mean that patient choice is paramount. This review covers the investigation, diagnosis and management of individuals with suspected MPE. It details the strategies available for definitive MPE management, explores which approaches to consider in different situations, and describes how to manage potential complications. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_31 GBV_ILN_2004 GBV_ILN_2111 GBV_ILN_2336 GBV_ILN_4251 |
| title_short |
Managing pleural malignancy |
| remote_bool |
true |
| author2 |
Bibby, Anna Maskell, Nick A. |
| author2Str |
Bibby, Anna Maskell, Nick A. |
| ppnlink |
362773971 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.mpmed.2023.09.008 |
| up_date |
2024-07-06T23:43:53.465Z |
| _version_ |
1803875184506044416 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">ELV065638786</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20231118093014.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">231118s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.mpmed.2023.09.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV065638786</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1357-3039(23)00229-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lynch, Geraldine A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Managing pleural malignancy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pleural malignancy is a growing problem, with malignant pleural effusions (MPEs) affecting 70 per 100,000 people every year. Around 15% of all cancer patients are diagnosed with pleural malignancy during their cancer journey, and they are treated by general and respiratory physicians alike. MPEs usually indicate advanced or aggressive disease, with median survival typically 6–12 months. Symptoms can be debilitating, so effusion management and symptom control form key aspects of care. Management options for MPE have grown in recent years, and important differences in the benefits and disadvantages of the various methods mean that patient choice is paramount. This review covers the investigation, diagnosis and management of individuals with suspected MPE. It details the strategies available for definitive MPE management, explores which approaches to consider in different situations, and describes how to manage potential complications.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Indwelling pleural catheter</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">malignant pleural effusion</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pleural biopsy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pleurodesis</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bibby, Anna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maskell, Nick A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Medicine</subfield><subfield code="d">[Oxford] : Elsevier, 2002</subfield><subfield code="g">51, Seite 880-887</subfield><subfield code="w">(DE-627)362773971</subfield><subfield code="w">(DE-600)2100582-5</subfield><subfield code="w">(DE-576)271585617</subfield><subfield code="x">1878-9390</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:51</subfield><subfield code="g">pages:880-887</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="j">Medizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">51</subfield><subfield code="h">880-887</subfield></datafield></record></collection>
|
| score |
7.39876 |